HSDT - Helius Medical Technologies Inc Class A

HSDT - Helius Medical Technologies Inc Class A

https://heliusmedical.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Inside Helius Medical's $500 Million Raise - And Its Solana Treasury Plans - Helius Medical Tech ( NASDAQ:HSDT )

Benzinga • 0 minutes ago • score: 0.05

Helius stock trades at 17.89 million volume vs 351K average after $500 million offering. Over $750 million in stapled warrants priced at $10.134, exercisable for 3 years. Want to trade this news? Get access to the 34-0 income strategy that loves volatility →

Helius Medical Technologies ( HSDT ) Stock Is Surging Today: What's Happening? - Helius Medical Tech ( NASDAQ:HSDT )

Benzinga • 1 month, 3 weeks ago • score: 0.55

Helius Medical says its double-blind randomized clinical trial of active PoNS therapy met its primary endpoint. Helius will submit the results to the FDA for an indication in stroke during the third quarter.

Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements

GlobeNewswire • 2 months ago • score: 0.34

NEWTOWN, Pa., July 09, 2025 ( GLOBE NEWSWIRE ) -- Helius Medical Technologies, Inc. ( Nasdaq: HSDT ) ( "Helius" or the "Company" ) , a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius ...

Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Aebi Schmidt Holding ( NASDAQ:AEBI ) , AirJoule Technologies ( NASDAQ:AIRJ )

Benzinga • 2 months, 1 week ago • score: 0.16

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Helius Medical Technologies, Inc. HSDT fell sharply in today's pre-market trading. Helius Medical Technologies filed prospectus for $25 million share offering.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company is headquartered in Newtown, Pennsylvania.

52W High

$817.50

52W Low

$5.37

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.75

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.01

EV/Revenue (<3 favorable)

18.04

P/S (TTM) (<3 favorable)

21.69

P/B (<3 favorable)

1.06

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.66%

Institutions (25–75% balanced)

1.46%

Shares Outstanding

1,077,300

Float

1,077,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

295,000

Gross Profit (TTM)

-263,000

EPS (TTM)

-12356.89

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-77.26%

ROE (TTM) (>15% strong)

-3.44%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.76

Momentum

Bearish momentum

Value

-1.0824

Previous

-1.3028

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025